Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitehead, W E
Right arrow Articles by van Zanten, S J O V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitehead, W E
Right arrow Articles by van Zanten, S J O V.
Gut 1999;45(Suppl 2):II78-II79 ( September )

Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium

The first 150 words of the full text of this article appear below.

On 10 and 11 September 1998, about 125 participants met at a symposium in Vienna, Austria, with the goal of determining whether a consensus could be developed on the definition of responders in clinical trials in the functional gastrointestinal disorders. Present at this meeting were representatives of the Food and Drug Administration (FDA) (Robert Prizont, MD, and John Senior, MD*), a representative of the Japanese International Motility Society (Kei Matsueda, MD, PhD), academic investigators from around the world, and representatives of several pharmaceutical companies currently engaged in the development of therapeutic compounds for the functional gastrointestinal disorders. The discussion centered primarily on the irritable bowel syndrome (IBS), the functional gastrointestinal disorder for which there is the largest development program underway. However, the discussion also addressed the measurement of outcomes in functional constipation.

This conference was sponsored by the Multinational Working Teams to Develop Diagnostic Criteria for Functional Gastrointestinal Disorders (MWT). Over a two . . . [Full text of this article]




This article has been cited by other articles:


Home page
GutHome page
J C Y Wu, F K L Chan, J Y L Ching, W-K Leung, Y Hui, R Leong, S C S Chung, and J J Y Sung
Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial
Gut, February 1, 2004; 53(2): 174 - 179.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
J. A. Weydert, T. M. Ball, and M. F. Davis
Systematic Review of Treatments for Recurrent Abdominal Pain
Pediatrics, January 1, 2003; 111(1): e1 - 11.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1999 BMJ Publishing Group Ltd & British Society of Gastroenterology